Xinhua Pharmaceutical announced that the company has received the Drug Registration Certificate for Dapagliflozin Tablets approved and issued by the National Medical Products Administration. The drug is in tablet form, with specifications of 10 mg and 5 mg, registered as a Category 4 chemical drug. It is indicated for adult patients with type 2 diabetes and adult patients with heart failure, and is classified as a Category B drug under national medical insurance. In 2025, sales of dapagliflozin tablets in China's public medical institutions reached approximately 11.4 billion yuan. This approval will further enrich the company's product portfolio and help enhance its market competitiveness.
Shandong Xinhua Pharmaceutical Co LtdReceived drug registration certificate for dapagliflozin tablets, expanding product portfolio and market competitiveness.
